Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1990 1
1996 1
2001 1
2003 4
2004 1
2005 3
2006 2
2008 2
2009 3
2010 5
2011 7
2012 10
2013 8
2014 8
2015 9
2016 4
2017 11
2018 9
2019 15
2020 12
2021 12
2022 12
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
D'Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, Oliva S, Ledda A, Grasso M, Pavone V, Ronconi S, Vincelli ID, Ballanti S, Velluti C, Cellini C, Gozzetti A, Palmas AD, Gamberi B, Mancuso K, Paris L, Zambello R, Petrucci MT, Bruno B, Musto P, Gay F. D'Agostino M, et al. Among authors: pavone v. Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080. Blood. 2024. PMID: 38048557
Latent Mastocytosis Triggered by COVID-19 Vaccination: A Case Report.
Calogiuri G, Foti C, Congedo M, Nettis E, Paladini L, Greco G, Pavone V, Vacca A. Calogiuri G, et al. Among authors: pavone v. Endocr Metab Immune Disord Drug Targets. 2023 Oct 10. doi: 10.2174/0118715303241179230927105454. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2023. PMID: 37817657
Dye Decolorization by a Miniaturized Peroxidase Fe-MimochromeVI*a.
Chino M, La Gatta S, Leone L, De Fenza M, Lombardi A, Pavone V, Maglio O. Chino M, et al. Among authors: pavone v. Int J Mol Sci. 2023 Jul 4;24(13):11070. doi: 10.3390/ijms241311070. Int J Mol Sci. 2023. PMID: 37446248 Free PMC article.
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study.
Gini G, Tani M, Tucci A, Marcheselli L, Cesaretti M, Bellei M, Pascarella A, Ballerini F, Petrini M, Merli F, Olivieri A, Lanza F, Annibali O, Zilioli VR, Liberati AM, Tisi MC, Arcari A, Marino D, Musuraca G, Pavone V, Fabbri A, Pozzi S, Mannina D, Plenteda C, Celli M, Luminari S. Gini G, et al. Among authors: pavone v. Blood. 2023 Oct 26;142(17):1438-1447. doi: 10.1182/blood.2022019173. Blood. 2023. PMID: 37418685 Clinical Trial.
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, Pastore D. Mele G, et al. Among authors: pavone v. Leuk Lymphoma. 2023 Oct;64(10):1715-1718. doi: 10.1080/10428194.2023.2232487. Epub 2023 Jul 7. Leuk Lymphoma. 2023. PMID: 37417467 No abstract available.
132 results